Dutch company Enzyre has raised $11.85m (€12m) in a Series A financing round to accelerate the development of its ambulant diagnostic technology platform for haemophilia patients.
Led by new investor Oost NL, the financing round also saw participation from Demcon Investment and i&i Biotech Fund along with existing investors Novalis Biotech and Takeda Ventures.
Enzyre also said that a part of the funding comes from an innovation credit from the Dutch Government.
